Aravive Inc

NASDAQ:ARAV   4:00:00 PM EDT
1.34
-0.02 (-1.47%)
5:38:10 PM EDT: $1.34 0.00 (0.00%)
Earnings Announcements

Aravive Reports Q3 2022 Financial Results

Published: 11/10/2022 12:47 GMT
Aravive Inc (ARAV) - Aravive Reports Third Quarter 2022 Financial Results and Provides Corporate Updates.
Revenues for Three Months Ended September 30, 2022, Were About $4.9 Million, Compared to About $1.6 Million for Three Months Ended June 30, 2022.
Qtrly Loss per Share $0.51.
Q3 Earnings per Share View $-0.64, Revenue View $972000.00 -- Refinitiv Ibes Data (analyst estimates).
Aravive - Continued Advancement of Clinical Trials in Platinum Resistant Ovarian Cancer, Clear Cell Renal Cell Carcinoma, Pancreatic Adenocarcinoma.
Revenue is expected to be $0.71 Million
Adjusted EPS is expected to be -$0.33

Next Quarter Revenue Guidance is expected to be $0.5 Million
Next Quarter EPS Guidance is expected to be -$0.30

More details on our Analysts Page.